Literature DB >> 19723833

Class C CpG oligodeoxynucleotides as a single agent and in combination with radiotherapy efficiently delayed growth of subcutaneous B16F1 tumors.

Petra Cerkovnik1, Barbara Jezersek Novakovic, Vida Stegel, Srdjan Novakovic.   

Abstract

Until now, the anti-tumor efficacy of synthetic oligodeoxynucleotides containing CpG motifs (CpG ODNs) has been reported in a number of preventive and therapeutic tumor models. Predominately class B CpG ODNs were used, relatively little has been reported regarding the class C CpG ODNs. The present study was, therefore, aimed at assessing the ability of CpG ODNs class C applied as a single agent and in combination with radiotherapy to induce the anti-tumor immunity in an experimental tumor model in mice (subcutaneous [s.c.] B16F1). Class C CpG ODNs applied three times as a single agent efficiently delayed the growth of s.c. B16F1 tumors. The combined therapy (CpG ODNs and tumor irradiation) remarkably enhanced the anti-tumor effect. The peritumoral (p.t.) application of CpG ODNs in combination with irradiation increased the number of dendritic cells (DCs) at the tumor site and improved the antigen loading and maturation of DCs. In conclusion, the combined therapy with CpG ODNs and irradiation creates a unique in situ DCs vaccine that could be easily applicable without prior knowledge of tumor antigens.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19723833     DOI: 10.1177/1753425909105581

Source DB:  PubMed          Journal:  Innate Immun        ISSN: 1753-4259            Impact factor:   2.680


  5 in total

1.  Tumor vaccine composed of C-class CpG oligodeoxynucleotides and irradiated tumor cells induces long-term antitumor immunity.

Authors:  Petra Cerkovnik; Barbara Jezersek Novakovic; Vida Stegel; Srdjan Novakovic
Journal:  BMC Immunol       Date:  2010-09-13       Impact factor: 3.615

2.  CpG Oligodeoxynucleotides Enhance the Activities of CD8+ Cytotoxic T-Lymphocytes Generated by Combined hMUC1 Vaccination and hNIS Radioiodine Gene Therapy.

Authors:  Yong Hyun Jeon; Yun Choi; Jaetae Lee; Chul Woo Kim; June-Key Chung
Journal:  Nucl Med Mol Imaging       Date:  2010-07-13

3.  CpG plus radiotherapy: a review of preclinical works leading to clinical trial.

Authors:  Kathy A Mason; Nancy R Hunter
Journal:  Front Oncol       Date:  2012-08-14       Impact factor: 6.244

4.  Intravaginal TLR agonists increase local vaccine-specific CD8 T cells and human papillomavirus-associated genital-tumor regression in mice.

Authors:  S Domingos-Pereira; L Decrausaz; L Derré; M Bobst; P Romero; J T Schiller; P Jichlinski; D Nardelli-Haefliger
Journal:  Mucosal Immunol       Date:  2012-09-12       Impact factor: 7.313

Review 5.  CpG Oligodeoxynucleotides for Anticancer Monotherapy from Preclinical Stages to Clinical Trials.

Authors:  Zhongkun Zhang; Jimmy Chun-Tien Kuo; Siyu Yao; Chi Zhang; Hira Khan; Robert J Lee
Journal:  Pharmaceutics       Date:  2021-12-28       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.